Acceleron Pharma Inc (NASDAQ:XLRN) CFO Kevin F. Mclaughlin sold 4,000 shares of the firm’s stock in a transaction dated Tuesday, January 2nd. The stock was sold at an average price of $42.42, for a total transaction of $169,680.00. Following the completion of the transaction, the chief financial officer now directly owns 45,300 shares in the company, valued at approximately $1,921,626. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.
Acceleron Pharma Inc (XLRN) traded down $1.46 during trading hours on Thursday, hitting $42.94. 332,656 shares of the stock were exchanged, compared to its average volume of 275,733. Acceleron Pharma Inc has a twelve month low of $23.07 and a twelve month high of $44.80. The company has a market cap of $1,929.73, a PE ratio of -16.58 and a beta of 1.59.
Acceleron Pharma (NASDAQ:XLRN) last released its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.67) by $0.02. Acceleron Pharma had a negative net margin of 759.34% and a negative return on equity of 40.70%. The business had revenue of $3.00 million for the quarter, compared to analysts’ expectations of $3.52 million. During the same period last year, the business earned ($0.55) EPS. The company’s revenue was up .0% compared to the same quarter last year. sell-side analysts predict that Acceleron Pharma Inc will post -2.65 earnings per share for the current year.
Several research analysts recently commented on the stock. HC Wainwright raised their price target on shares of Acceleron Pharma from $57.00 to $62.00 and gave the stock a “buy” rating in a research note on Tuesday, November 7th. Oppenheimer reiterated a “hold” rating on shares of Acceleron Pharma in a report on Tuesday, November 14th. BidaskClub upgraded shares of Acceleron Pharma from a “hold” rating to a “buy” rating in a report on Wednesday, December 27th. Royal Bank of Canada began coverage on shares of Acceleron Pharma in a report on Thursday, September 14th. They set a “sector perform” rating and a $44.00 target price on the stock. Finally, UBS Group reiterated a “buy” rating and set a $50.00 target price (up from $36.00) on shares of Acceleron Pharma in a report on Tuesday, September 12th. Two analysts have rated the stock with a sell rating, six have issued a hold rating and twelve have assigned a buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $44.56.
TRADEMARK VIOLATION WARNING: This news story was originally posted by American Banking News and is owned by of American Banking News. If you are reading this news story on another domain, it was illegally copied and republished in violation of U.S. & international trademark and copyright law. The legal version of this news story can be accessed at https://www.americanbankingnews.com/2018/01/04/acceleron-pharma-inc-xlrn-cfo-kevin-f-mclaughlin-sells-4000-shares.html.
Acceleron Pharma Company Profile
Acceleron Pharma Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its research focuses on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta (TGF-beta), protein superfamily.
Receive News & Ratings for Acceleron Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acceleron Pharma and related companies with MarketBeat.com's FREE daily email newsletter.